Vireo Growth (OTCMKTS:VREOD – Get Free Report) and Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.
Analyst Recommendations
This is a summary of recent ratings for Vireo Growth and Dr. Reddy’s Laboratories, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
| Dr. Reddy’s Laboratories | 1 | 1 | 1 | 0 | 2.00 |
Dr. Reddy’s Laboratories has a consensus price target of $1,450.00, indicating a potential upside of 11,188.44%. Given Dr. Reddy’s Laboratories’ stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy’s Laboratories is more favorable than Vireo Growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
| Dr. Reddy’s Laboratories | 10.15% | 9.49% | 6.32% |
Valuation and Earnings
This table compares Vireo Growth and Dr. Reddy’s Laboratories”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
| Dr. Reddy’s Laboratories | $3.58 billion | 2.99 | $456.00 million | $0.44 | 29.19 |
Dr. Reddy’s Laboratories has higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Vireo Growth has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Dr. Reddy’s Laboratories has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Insider & Institutional Ownership
3.8% of Dr. Reddy’s Laboratories shares are owned by institutional investors. 3.8% of Vireo Growth shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy’s Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Dr. Reddy’s Laboratories beats Vireo Growth on 12 of the 14 factors compared between the two stocks.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Receive News & Ratings for Vireo Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vireo Growth and related companies with MarketBeat.com's FREE daily email newsletter.
